Previous 10 | Next 10 |
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Global Blood Therapeutics, Inc. (GBT) Q1 2020 Earnings Conference Call May 6, 2020 04:30 PM ET Company Participants Stephanie Yao - Senior Director of Investor Relations & Corporate Communications Ted Love - President & Chief Executive Officer Jeff Farrow - Chief Financia...
Global Blood Therapeutics (NASDAQ: GBT ): Q1 GAAP EPS of -$1.20 beats by $0.31 . Revenue of $14.12M beats by $10.47M . Press Release More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Achieved Oxbryta ® (voxelotor) net revenues of $14.1 million in first full quarter of launch Approximately 1,650 new patient prescriptions for Oxbryta during the first quarter Adapted to virtual operations and engagement intended to ensure ongoing access to Oxbryta during th...
Global Blood Therapeutics (NASDAQ: GBT ) is scheduled to announce Q1 earnings results on Wednesday, May 6th, after market close. The consensus EPS Estimate is -$1.55 (-78.2% Y/Y) and the consensus Revenue Estimate is $3.65M Over the last 2 years, GBT has beaten EPS estimates 38% of t...
SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2020 financial results on Wednesday, May 6, 2020, after U.S. financial markets close. Management will host a conference ca...
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs. More news on: Adverum Biotechnologies, Inc., Alector, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
An initial public offering (IPO) has a special allure: It draws in speculative investors eager to see stocks soar in the initial days of trading. In weak markets, only the strongest candidates pull off an IPO. Lesser-quality companies delay or withdraw the offering, typically citing market condi...
Sickle cell anemia is a genetic disorder that reduces the capacity of red blood cells to deliver oxygen to organs across the body. The disease is estimated to affect more than 100,000 Americans total and has a market worth billions globally. Up to 31% of patients with the condition may develop e...
Global Blood Therapeutics reports Q4 earnings, summarizes upcoming catalysts Global Blood Therapeutics' ( GBT ) novel sickle cell disease drug, Oxbryta , has officially hit the market, netting a mere $2M in revenue. Meanwhile, R&D costs have nearly doubled in the last year. SG&A...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...